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Purpose: In many studies of the pharmacogenetic effects of dosing the immunosuppressant drug, 
tacrolimus, a single allele of CYP3A5 (*3) is often the only one considered as it is the most frequent 
variant. This study’s purpose was to evaluate the incidence of two other CYP3A5 alleles when using 
single-SNP assays for genotype-guided tacrolimus dosing. Here, we investigated three CYP3A5 alleles 
including the wildtype (*1) and nonfunctional (*3, *6, *7) alleles. CYP3A5 non-expressers have two 
nonfunctional alleles, whereas patients with at least one wildtype allele are considered CYP3A5 
expressers and are recommended to be started on a higher tacrolimus dose. Pharmacogenomic studies 
have often only attempted to detect the presence of *3 for nonfunctional status and used a default to call 
of *1 in the absence of the *3 allele. The *3 allele is most common in Caucasians. The *6 and *7 alleles 
are more common in African Americans but are not routinely genotyped, resulting in potentially 
miscalled CYP3A5 genotypes and reduced clinical benefit from genotype-guided dosing.  
 
Methods: Initial genotyping (N=115) was conducted using a CLIA-validated TaqMan assay based on 
the presence of CYP3A5*3 (absence of *3 defaulted to *1). To determine if patients had miscalled 
genotypes, we also retrospectively determined the number of patients found to have CYP3A5*6 or *7 
alleles after further genotyping. A TaqMan allelic discrimination, qualitative polymerase chain reaction 
(qPCR) assay was used to test for *6 and *7 alleles.  
 
Results: Out of 115 patients, 64 CYP3A5 expressers were retested for nonfunctional status based on *6 
and *7. Patients that were already designated as *3/*3 were not tested again. Of the 23 patients who 
were *1/*1, 12 patients (52.2%) had a miscalled genotype: 11 patients had one copy of *6 or *7, and one 
patient had two nonfunctional alleles. Of the 41 patients who were *1/*3, 11 patients (26.8%) had a 
miscalled genotype and had two nonfunctional alleles. Altogether, 23 (36.0%) of the 64 patients had a 
miscalled genotype. 
 
Conclusion: This study assessed the importance of testing *6 and *7 alleles in a racially diverse kidney 
transplant recipient population. A comprehensive gene analysis may be beneficial for CYP3A5 
























Tacrolimus, a calcineurin inhibitor, is the cornerstone of immunosuppression in solid organ 
transplantation, including kidney transplantation. Tacrolimus is a narrow therapeutic index drug, which 
means that levels above the therapeutic range increase risk of toxicity, and levels below the therapeutic 
range increase risk of organ rejection. Maintaining therapeutic tacrolimus levels poses a challenge due to 
large intra- and inter-patient variability, which is partly attributed to pharmacogenomic variations in the 
CYP3A5 gene, which determines the metabolism and clearance of tacrolimus by the CYP3A5 enzyme.1,2 
This variability is particularly distinct between Caucasian and African American populations.  
 
Single-nucleotide polymorphisms (SNP) result in changes in the CYP3A5 gene, creating a nonfunctional 
protein or loss of expression of the functional protein.2 The functional (wildtype) allele is CYP3A5*1, 
whereas the notable nonfunctional alleles are CYP3A5*3, CYP3A5*6, and CYP3A5*7.1 CYP3A5 non-
expressers have any combination of two nonfunctional alleles, whereas patients with at least one copy of 
the wildtype allele are CYP3A5 expressers. Expressers are further classified into extensive metabolizers 
(*1/*1) and intermediate metabolizers (one wildtype and one nonfunctional allele: 1/*3, *1/*6, or 
*1/*7). Non-expressers or poor metabolizers could express any of the following genotypes: *3/*3, 
*6/*6, *7/*7, *3/*6, *3/*7, or *6/*7. Expressers have decreased dose-adjusted tacrolimus trough 
concentrations compared to non-expressers and require a higher total daily dose.1,4 Thus, the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) recommends an initial tacrolimus dose 1.5 – 2 
times higher than standard dose for CYP3A5 expressers as they metabolize tacrolimus to a greater extent 
than CYP3A5 non-expressers.1 Initial genotype-guided tacrolimus dosing has also been suggested to 
decrease time to reach stable therapeutic concentrations.1,5 
 
The current gap in knowledge is the utility of genotype-guided tacrolimus dosing in a racially diverse 
patient population. Pharmacogenomic studies in this area historically have used a single-SNP assay to 
determine patients’ metabolism status, where the assay detects for the presence of CYP3A5*3 for 
nonfunctional status and defaults to call the patient CYP3A5*1 in the absence of the CYP3A5*3 allele. 
Standard dosing is based on CYP3A5 non-expressers, where 80-85% of Caucasians are homozygous for 
the variant CYP3A5*3 allele.6 Whereas, this is often an adequate approach for transplant in Caucasian 
populations with the high frequency of the *3 allele and very low frequency of *6 and *7, transplant in 
patients particularly with African lineage, but also other ethnic groups, requires closer examination of 
CYP3A5 alleles. The variant CYP3A5*6 and CYP3A5*7 alleles are more common in African Americans 
but are rarely genotyped, resulting in potentially miscalled CYP3A5 wildtype genotypes and reduced 
clinical benefit from genotype-guided tacrolimus dosing. This is compelling because the US kidney 
transplant recipient population comprises approximately 30% African Americans, with even higher 
proportions in the southeast region of the country.4,7 
  
In the racially diverse US kidney transplant population, the consequence of not genotyping the correct 
alleles could be inappropriate immunosuppressant dose selection and worse patient outcomes. Our study 
aims to explore the importance of genotype testing CYP3A5*6 and CYP3A5*7 in addition to CYP3A5*3 












The objectives of this study were 1) to evaluate the differences in CYP3A5 alleles that were identified 
using two different assays for genotype-guided tacrolimus dosing in racially diverse kidney transplant 






Data for this study was obtained from an ongoing single-center, open-label, phase-4 trial conducted at 
University of North Carolina (UNC) Medical Center in Chapel Hill, NC. The study was approved by the 
institutional review board and an informed consent was obtained from each patient before study 
enrollment. Patients aged 18-65 years old who were kidney transplant recipients or those on the waitlist 
to receive kidney transplantation were studied. All patients received genotype testing at time of study 
consent. The patients’ races were collected through the electronic health record (EHR) as self-reported 
by the patient (Caucasian, African American, Hispanic, Asian, American Indian, or other). 
 
Genotype testing  
CYP3A5 genotype testing was performed on de-identified patient DNA isolated from a buccal swab. All 
patients received genotype testing of CYP3A5*3 alleles (rs776746,g.6986A>G),  at time of study 
consent. Single-nucleotide polymorphisms CYP3A5*6 (rs10264272, g.14690 G>A) and CYP3A5*7 
(rs41303343, g.27131-27132insT) were genotyped retrospectively, as these alleles were found to be 
significant in our target population.2,4 
 
Assay 1 
All patients received initial genotype testing using a CLIA (Clinical Laboratory Improvement 
Amendment) -validated TaqMan assay. This single-SNP assay tested for metabolism status based on the 
presence of CYP3A5*3. The absence of CYP3A5*3 defaulted in classifying the patient as CYP3A5*1. 
This assay was chosen for initial genotype testing because it was most readily available and used in 
historical pharmacogenomic studies. Patient genotype was recorded (*1/*1, *1/*3, or *3/*3).  
 
Assay 2 
To determine if any patients had miscalled wildtype genotypes, all CYP3A5 expressers identified using 
Assay 1 were retested for nonfunctional metabolism status based on CYP3A5*6 and CYP3A5*7. 
CYP3A5 non-expressers were not eligible for retesting because they were already confirmed to having 
two copies of CYP3A5*3. A TaqMan allelic discrimination qualitative polymerase chain reaction 
(qPCR) assay was used to test for the CYP3A5*6 and CYP3A5*7 alleles. Patient genotype was 
reassigned (*1/*1, *1/*3, *1/*6, *1/*7, *3/*3, *6/*6, *7/*7, *3/*6, *3/*7, or *6/*7). 
 
We used descriptive statistics to report the baseline patient characteristics and percentages of genotype, 















There were 115 patients who were genotyped for the presence of CYP3A5*3 allele. Notably, the 
majority of our patients were African American (53%), followed by Caucasian (34%) or other race 
(10%). A total of 51 patients had 2 copies of CYP3A5*3 and were described as non-expressers. There 
were 41 patients with one copy of CYP3A5*3 and were described as intermediate metabolizers or 
expressers. The remaining 23 patients were called as CYP3A5*1/*1 due to the absence of CYP3A5*3 
and were described as extensive metabolizers or expressers. 
 
Table 1 stratifies the CYP3A5 expression results based on race and genotype. The table depicts the 
number and proportion of extensive, intermediate, and poor metabolizers by race based on Assay 1. Of 
the 64 CYP3A5 expressers (extensive and intermediate metabolizers), 56 patients (87.5%) were African 
American and 3 were Caucasian (4.7%). Of the 51 CYP3A5 non-expressers (poor metabolizers), 39 
patients (76.5%) were Caucasian and 5 were African American (9.8%). Of the 61 African American 
patients, 56 (91.8%) were CYP3A5 expressers. Of the 42 Caucasian patients, 39 (92.9%) were CYP3A5 
non-expressers.  
 
Race EM (*1/*1) IM (*1/*3) PM (*3/*3) 
AA (n=61) 21 (91.3%) 35 (85.4%) 5 (9.8%) 
Caucasian (n=42) 1 (4.3%) 2 (4.9%) 39 (76.5%) 
Hispanic (n=6) 0 (0.0%) 4 (9.8%) 2 (7.8%) 
Asian (n=5) 1 (4.3%) 0 (0.0%) 4 (3.9%) 
American Indian 
(n=1)  
0 (0.0%) 0 (0.0%) 1 (2.0%) 
Overall (n=115) 23 (20.0%) 41 (35.7%) 51 (44.3%) 







Figure 1 illustrates the proportion of extensive, intermediate, and poor metabolizers after initial 
genotype testing using Assay 1. 
 
After the 64 CYP3A5 expressers were retested using Assay 2 for nonfunctional status based on *6 and 
*7, 23 patients (36.0%) were found to have at least one copy of *6 or *7, illustrating miscalled initial 
genotypes.  
 
Of the 23 patients who were originally classified as *1/*1, 12 patients (52.2%) had a miscalled 
genotype: 11 patients (48%) had one copy of *6 or *7, and one patient (4%) had two copies of the 
nonfunctional allele (Figure 2).  
 
Of the 41 patients who were originally classified as *1/*3, 11 patients (26.8%) had a miscalled genotype 
and had two nonfunctional alleles (Figure 3). 
 
Figure 4 illustrates the proportion of extensive, intermediate, and poor metabolizers after re-genotype 
testing using Assay 2.   
 
Of the 23 patients who had a miscalled genotype, 22 patients (95.7%) were African American, and 1 




Figure 1. The total proportion of extensive, intermediate, and poor metabolizers based on presence of 




Figure 2. Patients who were found to be extensive metabolizers based on Assay 1 were retested for 
CYP3A5*6 and CYP3A5*7 using Assay 2. This figure shows the subsequent re-classification of patients 
after testing via Assay 2 (n=23) 
 
 
Figure 3. Patients who were found to be intermediate metabolizers based on Assay 1 were retested for 
CYP3A5*6 and CYP3A5*7 using Assay 2. This figure shows the subsequent re-classification of patients 
after testing via Assay 2 (n=41).  
 
 
Figure 4. The total proportion of extensive, intermediate, and poor metabolizers based on presence of 
CYP3A5*3, CYP3A5*6, and CYP3A5*7 after using Assay 2 (n=115).  
 
 
Race Patients With At 
Least One Copy of 
*6 or *7 
AA  22 (95.7%) 
Caucasian  1 (4.3%) 
Hispanic  0 (0.0%) 
Asian  0 (0.0%) 
American Indian  0 (0.0%) 
Overall  23 (35.9%) 








While tacrolimus is the mainstay immunosuppressant agent in solid organ transplantation, including 
kidney transplantation, ensuring its therapeutic efficacy and safety poses several challenges. 
Pharmacogenomic variations in the CYP3A5 gene have been studied as a key determinant of variability 
in therapeutic tacrolimus trough levels between individual patients and different races, particularly 
between Caucasians and African Americans. 
  
The CYP3A5 gene has a high estimated allele frequency across various populations. Specifically, the 
nonfunctional allele CYP3A5*3 has a difference in frequency across populations, including Caucasians 
(88% to 95%), Japanese (85%), Southeast Asians excluding Japanese and Chinese (67%), Chinese 
(65%), Pacific Islanders (65%), Southwest American Indians (40%), and African Americans (18-
33%).2,3,6,8-13 Conversely, in African Americans, the variants CYP3A5*6 and CYP3A5*7 alleles have a 
minor frequency of 16-18% and 10-12% respectively.2,3,11-12,14-15 Furthermore, these nonfunctional 
alleles are virtually absent in Caucasians.  
 
The current gap in knowledge is the utility of genotype-guided tacrolimus dosing in a racially diverse 
patient population. Pharmacogenomic studies in this area historically use single-SNP assays to 
determine patients’ metabolism status, wherein the assay only detects for the presence of CYP3A5*3 for 
nonfunctional status and defaults to call the patient CYP3A5*1 in the absence of the CYP3A5*3 allele.  
Standard tacrolimus dosing is based on CYP3A5 non-expressers, where the vast majority of Caucasians 
are homozygous for the variant CYP3A5*3 allele and are therefore non-expressers.6,8 As a result, 
genotype-guided dosing (or the lack thereof) in a primarily Caucasian population does not have a great 
clinical impact because the functional CYP3A5 enzyme is not common in this population. A 
randomized controlled trial conducted in the Netherlands evaluated the clinical outcomes of genotype-
guided dosing versus standard dosing and did not conclude any statistically significant results.16 This is 
likely due to Caucasians representing the majority of their study population (78%), and thus receiving 
the same standard dose regardless of being placed into the genotype-guided dosing study arm. This 
study only comprised 15% CYP3A5 expressers.  
 
Genotype-guided dosing is only beneficial for patients with a functional CYP3A5 enzyme. It has been 
understood that African Americans are more likely than Caucasians to have the functional CYP3A5 
enzyme; however, this premise is also based on the traditional CYP3A5*3 single-SNP assay. The other 
variant CYP3A5*6 and CYP3A5*7 alleles are more common in African Americans and virtually not 
present in Caucasians.4 This illustrates the wide range of genotypes African Americans can express.2 The 
presence of two CYP3A5*6 or CYP3A5*7 alleles in an African American would warrant the standard 
tacrolimus dose, similar to most Caucasians. Furthermore, CYP3A5*6 and CYP3A5*7 are rarely 
genotyped, resulting in potentially miscalled CYP3A5 wildtype genotypes and reduced clinical benefit 
from genotype-guided tacrolimus dosing. This is compelling because the US kidney transplant recipient 
population comprises approximately 30% African Americans, with even higher proportions in the 
southeast region of the country.2,7  
 
As a prominent kidney transplant center in the US southeast region, UNC Medical Center conducts 
approximately 80 kidney transplants per year. Of those 80 kidney transplant recipients, approximately 
60% are Caucasian and 40% are African Americans. Thus, we expected a higher proportion of African 
Americans in our study compared to historical studies.4,5,16 A racially diverse study population allowed 
us to better assess the utility of genotype-guided dosing. The majority of our study population was 
African American (53%) and the minority was Caucasian (36.5%) or other race (10.5%). 
 
Because our study’s initial genotype testing was based on the presence of CYP3A5*3, the rates of 
expression status were consistent with historical data: African Americans were more commonly 
expressers whereas Caucasians were more commonly non-expressers. When CYP3A5*6 and CYP3A5*7 
were tested among the 64 CYP3A5 expressers, over 1/3 (36%) of patients had a miscalled initial 
genotype.  
 
Of these patients who had at least one copy of CYP3A5*6 or CYP3A5*7, 96% were African American. 
Our allele frequencies are consistent with existing literature. A study conducted in Eastern North 
Carolina evaluated the prevalence of CYP3A5 variants across race-ethnicities and found that African 
Americans were the only population to express CYP3A5*6 or CYP3A5*7.4 Caucasians, Hispanics, 
Asians, and Native Americans only expressed the variant CYP3A5*3 allele. Another study that 
examined similar alleles reported 90-95% of their Caucasian population having at least one CYP3A5*3 
allele as opposed to the other CYP3A5 variants.2 Both of these studies reported that CYP3A5*6 and 
CYP3A5*7 have dose requirements equivalent to CYP3A5*3, which is consistent with CPIC 
guidelines.1,2,4 Among the 64 patients initially classified as expressers in our study, 12 patients (19%) 
were actually found to be non-expressers, which would warrant a dose change based on genotype-
guided dosing. The clearance of tacrolimus in the 12 non-expressers was initially overestimated by up to 
50%.2 Consequently, our data suggests that only genotype testing for CYP3A5*3 in African American 
patients may be harmful.  
 
In our study, when CYP3A5*6 and CYP3A5*7 were tested, more patients were classified as poor 
metabolizers and less patients were classified as extensive metabolizers than when CYP3A5*3 was 
tested alone. CYP3A5*6 and CYP3A5*7 are not routinely tested, resulting in potentially miscalled 
wildtype genotypes, especially among African Americans. Potentially miscalled CYP3A5 wildtype 
genotypes may reduce clinical benefit from genotype-guided tacrolimus dosing, resulting in 
inappropriate immunosuppressant dose selection which could cause negative clinical outcomes. Our 
study suggests that a comprehensive multi-allele panel (CYP3A5*3, CYP3A5*6, and CYP3A5*7) may 
provide increased accuracy of CYP3A5 genotypes.  
 
When pharmacogenomic testing is conducted in a racially diverse patient population, it is important that 
all of the relevant alleles are represented. Our study addresses this gap in knowledge by exploring the 
prevalence of CYP3A5*6 and CYP3A5*7 in a racially diverse kidney transplant recipient population. 
The impact of our study may guide future research in determining the long-term clinical utility of using 
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